Vericel Corporation $VCEL Stock: Summit Creek Advisors LLC Lowers Stake

Summit Creek Advisors LLC reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 21.6% during the third quarter, Holdings Channel.com reports. The fund owned 171,883 shares of the biotechnology company’s stock after selling 47,429 shares during the period. Vericel makes up about 2.8% of Summit Creek Advisors LLC’s portfolio, making the stock its 6th biggest position. Summit Creek Advisors LLC’s holdings in Vericel were worth $6,899,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Pictet Asset Management Holding SA boosted its holdings in Vericel by 15.4% in the third quarter. Pictet Asset Management Holding SA now owns 8,027 shares of the biotechnology company’s stock valued at $322,000 after acquiring an additional 1,071 shares during the last quarter. Alps Advisors Inc. raised its holdings in Vericel by 31.7% during the 3rd quarter. Alps Advisors Inc. now owns 67,860 shares of the biotechnology company’s stock worth $2,724,000 after purchasing an additional 16,331 shares during the last quarter. Provenance Wealth Advisors LLC bought a new position in Vericel during the 3rd quarter worth approximately $242,000. Bridge City Capital LLC lifted its position in shares of Vericel by 21.7% in the 3rd quarter. Bridge City Capital LLC now owns 65,161 shares of the biotechnology company’s stock worth $2,616,000 after purchasing an additional 11,627 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Vericel in the 3rd quarter worth approximately $105,000.

Insider Transactions at Vericel

In related news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total transaction of $778,800.00. Following the transaction, the insider owned 1,990 shares in the company, valued at $103,320.80. The trade was a 88.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 3,000 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $52.23, for a total transaction of $156,690.00. Following the transaction, the director directly owned 32,995 shares in the company, valued at approximately $1,723,328.85. This represents a 8.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,000 shares of company stock valued at $1,128,340 in the last quarter. 7.60% of the stock is currently owned by company insiders.

Vericel Price Performance

NASDAQ VCEL opened at $54.62 on Friday. The business has a 50 day simple moving average of $41.01 and a 200 day simple moving average of $38.90. Vericel Corporation has a one year low of $28.95 and a one year high of $55.60. The stock has a market capitalization of $2.80 billion, a P/E ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The company’s revenue was up 26.5% compared to the same quarter last year. Equities analysts expect that Vericel Corporation will post 0.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VCEL. TD Cowen upped their price objective on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Wall Street Zen raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a report on Thursday, July 30th. HC Wainwright upped their price target on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Friday. Finally, Truist Financial set a $65.00 price target on Vericel in a report on Friday. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.80.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.